A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000720
Collaborator
(none)
250
51
4.9

Study Details

Study Description

Brief Summary

To evaluate the clinical, immunologic, and virologic effects of oral zidovudine (AZT) plus intravenous immunoglobulin (IVIG) versus AZT plus placebo (albumin). It is estimated that by 1991, there may be 10,000 to 20,000 HIV-infected children in the United States. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in changing the course of disease and decreasing mortality in this vulnerable population. AZT treatment has been shown to decrease mortality and the frequency of opportunistic infections in certain adult AIDS patients; therefore, it is likely that children may also benefit from this antiviral therapy. In addition, bacterial infections are frequently found in HIV-infected children. Because pooled human serum immunoglobulin, another name for antibodies, is effective in reducing bacterial infection in patients with defects of immunity, it may reduce the rate of bacterial infection in HIV-infected children as well. In this study, AZT will be administered together with IVIG to determine safety, tolerance, and efficacy of the combined treatment.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

It is estimated that by 1991, there may be 10,000 to 20,000 HIV-infected children in the United States. HIV infection in children is most often associated with symptomatic disease and poor prognosis. Treatment with antiviral therapy may be effective in changing the course of disease and decreasing mortality in this vulnerable population. AZT treatment has been shown to decrease mortality and the frequency of opportunistic infections in certain adult AIDS patients; therefore, it is likely that children may also benefit from this antiviral therapy. In addition, bacterial infections are frequently found in HIV-infected children. Because pooled human serum immunoglobulin, another name for antibodies, is effective in reducing bacterial infection in patients with defects of immunity, it may reduce the rate of bacterial infection in HIV-infected children as well. In this study, AZT will be administered together with IVIG to determine safety, tolerance, and efficacy of the combined treatment.

The study includes 250 children, 3 months to 12 years of age. All participants receive oral AZT. IVIG or intravenous placebo is administered every 28 days. Patients are followed for the development of serious bacterial infection, as well as for a number of factors relating to safety, tolerance, progression of disease, and survival. This is an outpatient study conducted over a minimum 100-week period. The children are evaluated every 2 weeks for the first 8 weeks, and monthly thereafter.

Study Design

Study Type:
Interventional
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine
Actual Study Completion Date :
Apr 1, 1993

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    3 Months to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Benadryl and/or acetaminophen may be given before and during intravenous immunoglobulin (IVIG) infusion in patients demonstrating mild reactions during infusion.

    • Acetaminophen for short-term fever and pain.

    • Zidovudine (AZT).

    • Steroids.

    • Oral or systemic (swish and swallow) nystatin.

    • Maintenance therapy for fungal disease or tuberculosis.

    • Prophylaxis for a previous episode of Pneumocystis carinii pneumonia (PCP) including the use of trimethoprim / sulfamethoxazole (TMP / SMX). The dosage is specified as TMP 75 mg/m2 twice daily 3 times a week and SMX 375 mg/m2 twice daily 3 times a week.

    • Recommended:

    • Children with AIDS and / or CD4 count = or < 500 cells/mm3 should receive primary PCP prophylaxis as described.

    Concurrent Treatment:
    Allowed:
    • Blood transfusion for hemoglobin < 8 g/dl and hematocrit < 24 percent or bone marrow suppression.

    • Supplemental oxygen with a prestudy PaO2 < 70 mmHg.

    Children must have one or more of the indicator diseases of AIDS; however, there must be an absence of acute opportunistic infection and an absence of bacterial infection requiring treatment at the time of entry into the study.

    • Children with lymphoid interstitial proliferation (LIP) are excluded from enrollment unless they have had additional AIDS-defining opportunistic infections, meet ARC criteria, have had two or more serious bacterial infections in the 12 months prior to study entry, have evidence of HIV encephalopathy, or are currently on supplemental oxygen and steroids with a pre-treatment PaO2 < 70 mm Hg.

    • Children with concurrent LIP and ARC are eligible for inclusion. Thrombocytopenia is an exclusion except if it is HIV-associated.

    • Children randomized prior to their 13th birthday are eligible.

    • All lab values must be within 4 weeks of study entry.

    Prior Medication:
    Allowed:
    • Zidovudine (AZT).

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following will be excluded:
    • Lymphoid interstitial proliferation (LIP) not requiring steroids and supplemental oxygen or with other lymphoproliferative diseases as their sole clinical evidence of HIV infection.

    • Known hypersensitivity to immunoglobulin.

    • Active HIV thrombocytopenia requiring IVIG therapy.

    Concurrent Medication:
    Excluded:
    • Chronic acetaminophen.

    • Drugs that are metabolized by hepatic glucuronidation should not be used for more than 24 hours without notifying the study physician.

    • Antibacterial prophylaxis for otitis, sinusitis, or urinary tract infection.

    • Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP) prior to the first episode of laboratory-documented PCP.

    • Immunoglobulin (IVIG) therapy required for active HIV thrombocytopenia.

    Patients with the following will be excluded:
    • Lymphoid interstitial proliferation (LIP) not requiring steroids and supplemental oxygen or with other lymphoproliferative diseases as their sole clinical evidence of HIV infection.

    • Known hypersensitivity to immunoglobulin.

    • Active HIV thrombocytopenia requiring IVIG therapy.

    • Inability to establish or maintain intravenous access.

    • Lack of parental or guardian authorization for intravenous access.

    Prior Medication:
    Excluded within 4 weeks of study entry:
    • Any other experimental therapy.

    • Other antiretroviral agents.

    • Drugs which cause prolonged neutropenia or significant nephrotoxicity.

    • Immunoglobulins.

    • Immunomodulating agents.

    Active alcohol or drug abuse.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Kaiser Permanente / UCLA Med Ctr Downey California United States 902422814
    2 Long Beach Memorial (Pediatric) Long Beach California United States 90801
    3 Children's Hosp of Los Angeles/UCLA Med Ctr Los Angeles California United States 900276016
    4 Los Angeles County - USC Med Ctr Los Angeles California United States 90033
    5 Cedars Sinai / UCLA Med Ctr Los Angeles California United States 900481804
    6 Martin Luther King Jr Gen Hosp / UCLA Med Ctr Los Angeles California United States 900593019
    7 UCLA Med Ctr / Pediatric Los Angeles California United States 900951752
    8 Stanford Univ School of Medicine Menlo Park California United States 94025
    9 Children's Hosp of Oakland Oakland California United States 946091809
    10 Univ of California / San Diego Treatment Ctr San Diego California United States 921036325
    11 Northern California Pediatric AIDS Treatment Ctr / UCSF San Francisco California United States 94143
    12 Olive View Med Ctr Sylmar California United States 91342
    13 Univ of Connecticut Health Ctr / Pediatrics Farmington Connecticut United States 06032
    14 Emory Univ School of Medicine Atlanta Georgia United States 30303
    15 Cook County Hosp Chicago Illinois United States 60612
    16 Univ of Illinois College of Medicine Chicago Illinois United States 60612
    17 Chicago Children's Memorial Hosp Chicago Illinois United States 606143394
    18 Tulane Univ School of Medicine New Orleans Louisiana United States 70112
    19 Univ of Maryland at Baltimore / Univ Med Ctr Baltimore Maryland United States 21201
    20 Children's Hosp of Boston Boston Massachusetts United States 021155724
    21 Boston Med Ctr Boston Massachusetts United States 02118
    22 Univ of Massachusetts Med Ctr Worcester Massachusetts United States 01655
    23 Univ of Minnesota Minneapolis Minnesota United States 55455
    24 Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl Newark New Jersey United States 071072198
    25 Lincoln Hosp Ctr / Pediatrics Bronx New York United States 10451
    26 Albert Einstein College of Medicine Bronx New York United States 10461
    27 SUNY / Health Sciences Ctr at Brooklyn / Pediatrics Brooklyn New York United States 11203
    28 City Hosp Ctr at Elmhurst / Mount Sinai Hosp Elmhurst New York United States 11373
    29 Schneider Children's Hosp / Long Island Jewish Med Ctr New Hyde Park New York United States 11042
    30 Beth Israel Med Ctr / Pediatrics New York New York United States 10003
    31 Bellevue Hosp / New York Univ Med Ctr New York New York United States 10016
    32 Saint Luke's - Roosevelt Hosp Ctr New York New York United States 10025
    33 Metropolitan Hosp Ctr New York New York United States 10029
    34 Mount Sinai Med Ctr New York New York United States 10029
    35 Columbia Univ Babies' Hosp New York New York United States 10032
    36 Harlem Hosp Ctr New York New York United States 10037
    37 Univ of Rochester Medical Center Rochester New York United States 14642
    38 Westchester Hosp / New York Med College / Pediatrics Valhalla New York United States 10595
    39 Duke Univ Med Ctr Durham North Carolina United States 277103499
    40 Holmes Hosp / Univ of Cincinnati Med Ctr Cincinnati Ohio United States 452670405
    41 Univ Hosp of Cleveland / Case Western Reserve Univ Cleveland Ohio United States 44106
    42 Columbus Children's Hosp Columbus Ohio United States 432052696
    43 Ohio State Univ Hosp Clinic Columbus Ohio United States 432101228
    44 Saint Christopher's Hosp for Children Philadelphia Pennsylvania United States 191341095
    45 Julio Arroyo West Columbia South Carolina United States 29169
    46 Hermann Hosp / Univ Texas Health Science Ctr Houston Texas United States 77030
    47 Texas Children's Hosp / Baylor Univ Houston Texas United States 77030
    48 Children's Hosp of Seattle Seattle Washington United States 98105
    49 Ramon Ruiz Arnau Univ Hosp / Pediatrics Bayamon Puerto Rico 00619
    50 San Juan City Hosp San Juan Puerto Rico 009367344
    51 UPR Children's Hosp / San Juan City Hosp San Juan Puerto Rico 00936

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)

    Investigators

    • Study Chair: Spector, SA,

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT00000720
    Other Study ID Numbers:
    • ACTG 051
    • 11025
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Nov 3, 2021
    Last Verified:
    Oct 1, 2021

    Study Results

    No Results Posted as of Nov 3, 2021